SOPHiA GENETICS Future Growth
Future criteria checks 1/6
SOPHiA GENETICS is forecast to grow earnings and revenue by 19.7% and 16.6% per annum respectively. EPS is expected to grow by 20.7% per annum. Return on equity is forecast to be -64% in 3 years.
Key information
19.7%
Earnings growth rate
20.7%
EPS growth rate
| Healthcare Services earnings growth | 32.7% |
| Revenue growth rate | 16.6% |
| Future return on equity | -64.0% |
| Analyst coverage | Good |
| Last updated | 18 Dec 2024 |
Recent future growth updates
Recent updates
Is SOPHiA GENETICS (NASDAQ:SOPH) A Risky Investment?
Oct 03
SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported, And Analysts Assigned A US$6.00 Price Target
Aug 09Investors Still Waiting For A Pull Back In SOPHiA GENETICS SA (NASDAQ:SOPH)
Aug 08SOPHiA GENETICS SA (NASDAQ:SOPH) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 09Sophia Genetics: Breakthrough Potential In A Cautious Healthcare Sector
Feb 12Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 27Why Investors Shouldn't Be Surprised By SOPHiA GENETICS SA's (NASDAQ:SOPH) 35% Share Price Surge
Nov 09Is SOPHiA GENETICS (NASDAQ:SOPH) In A Good Position To Invest In Growth?
Aug 08Here's Why We're Watching SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 15SOPHiA GENETICS partnering with Boundless Bio on oncogene cancer therapies
Sep 21SOPHiA Genetics GAAP EPS of -$0.39 in-line, revenue of $11.7M misses by $0.25M
Aug 09We're Hopeful That SOPHiA GENETICS (NASDAQ:SOPH) Will Use Its Cash Wisely
Jul 01SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 18We Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business Growth
Mar 10Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Nov 24Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 95 | -44 | N/A | -6 | 6 |
| 12/31/2025 | 77 | -57 | N/A | -26 | 6 |
| 12/31/2024 | 66 | -62 | N/A | -40 | 6 |
| 9/30/2024 | 64 | -71 | -52 | -44 | N/A |
| 6/30/2024 | 65 | -67 | -56 | -47 | N/A |
| 3/31/2024 | 64 | -73 | -57 | -48 | N/A |
| 12/31/2023 | 62 | -79 | -58 | -49 | N/A |
| 9/30/2023 | 59 | -69 | -58 | -48 | N/A |
| 6/30/2023 | 54 | -78 | -68 | -58 | N/A |
| 3/31/2023 | 51 | -82 | -77 | -67 | N/A |
| 12/31/2022 | 48 | -87 | -80 | -70 | N/A |
| 9/30/2022 | 45 | -95 | -84 | -75 | N/A |
| 6/30/2022 | 44 | -93 | -77 | -69 | N/A |
| 3/31/2022 | 42 | -86 | -73 | -65 | N/A |
| 12/31/2021 | 40 | -74 | -65 | -58 | N/A |
| 9/30/2021 | 37 | -63 | -58 | -52 | N/A |
| 6/30/2021 | 34 | -52 | -51 | -46 | N/A |
| 3/31/2021 | 30 | -41 | -39 | -35 | N/A |
| 12/31/2020 | 28 | -39 | -35 | -32 | N/A |
| 12/31/2019 | 25 | -34 | -35 | -32 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SOPH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SOPH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SOPH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SOPH's revenue (16.6% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: SOPH's revenue (16.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SOPH is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 11:03 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SOPHiA GENETICS SA is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |
| Katie Tryhane | Credit Suisse |